70% of WHO Vaccines and 14% of US Generics Sourced From India

India supplies 70% of the vaccines procured by the World Health Organization, showcasing its vital contribution to global public health. This highlights the country’s growing leadership in pharmaceutical manufacturing and international healthcare initiatives.

India Supplies 70% of WHO Vaccines

India supplies a significant 70% of vaccines sourced by the World Health Organization (WHO), reaffirming its critical role in global immunisation efforts. This was stated by Ms. Anupriya Patel, Union Minister of State for Health & Family Welfare and Chemicals & Fertilisers, during her address at the Second Policymakers’ Forum organised by the Indian Pharmacopoeia Commission (IPC). The minister underscored India’s ability to meet global healthcare demands through its robust pharmaceutical manufacturing ecosystem.

14% of Generic Drugs Imported By The United States Are from India

India’s impact on the pharmaceutical supply chain extends to the United States as well, with 14% of generic drugs imported by the US being manufactured in India. This reflects the trust placed in Indian pharmaceutical firms to deliver quality generics at scale, especially to highly regulated markets.

Jan Aushadhi Kendras Driving Affordable Access To Medicines

Ms. Patel highlighted the success of the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), which aims to increase access to affordable medicines across India. Jan Aushadhi Kendras, under this scheme, have played a significant role in reducing out-of-pocket healthcare spending for Indian citizens. These centres are designed to deliver cost-effective, high-quality medications to the masses.

Vaccine Maitri Initiative Reinforces India's Global Commitment

During the COVID-19 pandemic, India launched the ‘Vaccine Maitri’ initiative, supplying vaccines to over 100 partner nations. This humanitarian effort showcased India’s leadership in supporting global health equity and solidified its position as the “pharmacy of the world.”

Indian Generics Continue To Lead In Highly Regulated Markets

India exports 70% of its generic pharmaceutical products to highly regulated international markets, a testament to the country’s adherence to stringent quality standards. The country has also attained Maturity Level 3 (ML3) under WHO’s Global Benchmarking Tool (GBT), reflecting the competence and robustness of its drug regulatory system.

Highest Number Of US FDA-Approved Facilities Outside The US

India has the largest number of drug manufacturing facilities approved by the United States Food and Drug Administration (US FDA) outside the US. This widespread approval not only supports export growth but also enhances confidence in Indian medicines worldwide.

Read More: Trump Organization Launches $499 Gold Smartphone and Mobile Network! 

Conclusion 

In a move towards international regulatory harmonisation, 15 countries including Cuba now recognise the Indian Pharmacopoeia. This recognition enhances global pharmaceutical trade alignment and improves access to safe and effective medicines by streamlining quality benchmarks across borders.

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.